321 results on '"Dwoskin, Linda"'
Search Results
2. Methamphetamine effects in zebrafish (Danio rerio) depend on behavioral endpoint, dose and test session duration
3. Short-term CaMKII inhibition with tatCN19o does not erase pre-formed memory in mice and is neuroprotective in pigs
4. Varenicline serves as the training stimulus in the drug-discriminated goal-tracking task with rats: initial evaluation of potential neuropharmacological processes
5. Toward isolating reward changes in diet-induced obesity: A demand analysis
6. N,N′-diaryl-bishydrazones in a biphenyl platform: Broad spectrum antifungal agents
7. Tobacco's minor alkaloids: Effects on place conditioning and nucleus accumbens dopamine release in adult and adolescent rats
8. Competency, Programming, and Emerging Innovation in Graduate Education within Schools of Pharmacy: The Report of the 2016-2017 Research and Graduate Affairs Committee
9. Obesity: Current and potential pharmacotherapeutics and targets
10. GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2
11. Bis(N-amidinohydrazones) and N-(amidino)-N′-aryl-bishydrazones: New classes of antibacterial/antifungal agents
12. Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats
13. Necessity for research directed at stimulant type and treatment-onset age to access the impact of medication on drug abuse vulnerability in teenagers with ADHD
14. Adolescent d-amphetamine treatment in a rodent model of ADHD: Pro-cognitive effects in adolescence without an impact on cocaine cue reactivity in adulthood
15. Semisynthetic aurones inhibit tubulin polymerization at the colchicine-binding site and repress PC-3 tumor xenografts in nude mice and myc-induced T-ALL in zebrafish
16. Role of serotonin transporter function in rat orbitofrontal cortex in impulsive choice
17. Dissociable roles of dopamine and serotonin transporter function in a rat model of negative urgency
18. Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of attention deficit hyperactivity disorder
19. Methylphenidate treatment beyond adolescence maintains increased cocaine self-administration in the spontaneously hypertensive rat model of attention deficit/hyperactivity disorder
20. Effect of environmental enrichment on dopamine and serotonin transporters and glutamate neurotransmission in medial prefrontal and orbitofrontal cortex
21. Blockade of α2-adrenergic receptors in prelimbic cortex: impact on cocaine self-administration in adult spontaneously hypertensive rats following adolescent atomoxetine treatment
22. Environmental enrichment reduces methamphetamine cue-induced reinstatement but does not alter methamphetamine reward or VMAT2 function
23. Effects of dopamine D1 receptor blockade in the prelimbic prefrontal cortex or lateral dorsal striatum on frontostriatal function in Wistar and Spontaneously Hypertensive Rats
24. Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats
25. New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders
26. Adolescent d-amphetamine treatment in a rodent model of attention deficit/hyperactivity disorder: impact on cocaine abuse vulnerability in adulthood
27. Synthesis and evaluation of novel azetidine analogs as potent inhibitors of vesicular [3H]dopamine uptake
28. Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats
29. Angiotensin AT1 and AT2 receptor antagonists modulate nicotine-evoked [3H]dopamine and [3H]norepinephrine release
30. Adolescence methylphenidate treatment in a rodent model of attention deficit/hyperactivity disorder: Dopamine transporter function and cellular distribution in adulthood
31. Potential therapeutic uses of mecamylamine and its stereoisomers
32. Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: Methylphenidate vs. atomoxetine treatments
33. The effect of switching pharmacological intervention during extinction on nicotine-evoked conditioned responding in rats
34. r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement
35. Isolation rearing as a preclinical model of attention/deficit-hyperactivity disorder
36. The novel small molecule α9α10 nicotinic acetylcholine receptor antagonist ZZ-204G is analgesic
37. Effect of environmental enrichment on methylphenidate-induced locomotion and dopamine transporter dynamics
38. Prefrontal cortex and drug abuse vulnerability: Translation to prevention and treatment interventions
39. Indolizidine (−)-235B′ and related structural analogs: Discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [ 3H]dopamine release
40. Tolerance does not develop to the decrease in nicotine self-administration produced by repeated bupropion administration
41. Repeated nicotine administration robustly increases bPiDDB inhibitory potency at α6β2-containing nicotinic receptors mediating nicotine-evoked dopamine release
42. Mecamylamine, dihydro-β-erythroidine, and dextromethorphan block conditioned responding evoked by the conditional stimulus effects of nicotine
43. The novel nicotinic receptor antagonist, N, N′-dodecane-1,12-diyl- bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [ 3H]norepinephrine overflow from rat hippocampal slices
44. Nicotinic receptor-based therapeutics and candidates for smoking cessation
45. The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats
46. The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats
47. Extending the analysis of nicotinic receptor antagonists with the study of α6 nicotinic receptor subunit chimeras
48. First-principles determination of molecular conformations of indolizidine (−)-235B′ in solution
49. Vesicular monoamine transporter 2: Role as a novel target for drug development
50. Computational neural network analysis of the affinity of lobeline and tetrabenazine analogs for the vesicular monoamine transporter-2
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.